uploads/2019/02/hypertension-867855_1280-2.jpg

What Analysts Are Recommending for Teva Pharmaceutical This Month

By

Updated

Stock price movements

On February 15, Teva Pharmaceutical (TEVA) closed at $17.98, 4.05% higher than its previous closing price, 23.24% higher than its 52-week low of $14.59, and 30.74% lower than its 52-week high of $25.96. Its market cap was $20.00 billion, and its forward PE, price-to-sales, and price-to-book ratios were 6.37x, 1.01x, and 1.32x, respectively.

Peers Mylan (MYL), Allergan (AGN), and GlaxoSmithKline (GSK) are trading at forward PE ratios of 6.31x, 7.95x, and 13.63x, respectively.

Article continues below advertisement

After its fourth-quarter earnings release on February 13, Teva Pharmaceutical stock fell 5.96% from $19.12 on February 12 to $17.98 on February 15. The company reported revenue of $4.56 billion in the fourth quarter—$30 million higher than analysts’ consensus estimate despite being a YoY (year-over-year) fall of 15.6%. Teva also reported adjusted EPS of $0.53 in the quarter, a YoY fall of 43.01% and $0.02 lower than the consensus estimate.

Based on its closing price on February 15, the company reported returns of -1.32% in the last week, -3.59% in the last month, -23.59% in the last quarter, -19.98% in the last half year, -6.98% in the last year, and 16.60% YTD (year-to-date).

On February 15, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) reported returns of 3.24% in the last week, 5.22% in the last month, 1.98% in the last quarter, 3.25% in the last half year, 10.71% in the last year, and 7.33% YTD.

Teva Pharmaceutical has outperformed XLV YTD in 2019.

Analysts’ recommendations and target prices

Analysts’ 12-month consensus recommendation for Teva Pharmaceutical is a “hold.”

Of the 23 analysts covering Teva, two have given it “strong buys,” five have given it “buys,” 14 have given it “holds,” and two have given it “sells.” Their 12-month target price on the stock is $21.23, 18.08% higher than its closing price on February 15. The highest target price estimate for the stock is $30, and the lowest is $12.1.

Advertisement

More From Market Realist